moneyheap
CORT · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Corcept Therapeutics Inc. (CORT) stock moving?
Corcept reported a strong Q3 2026 on Nov 3: revenue rose 64% to $340.5M, EPS of $1.01 beat the $0.81 estimate, sales beat the $336.4M consensus, and 2026 revenue guidance of $1.1B-$1.2B was reiterated against a $1.146B estimate. Lifyorli revenue grew 92% to $91.4M, cash and investments reached $662.3M, and over 2,300 patients have received Lifyorli since its April launch. Analysts responded positively, with Piper Sandler reiterating Overweight and raising its target to $173 and the average target rising to $142.6. Despite this, the stock fell from $81.93 on Nov 3 to $71.63 on Nov 5, a drop the provided news does not explain, and closed at $73.35 on Nov 10. The stock is also down roughly 36% from the $115 level of Oct 22, and the Oct 23 drop to $85.86 on 3.1M shares is not explained by the provided items either. Benzinga flagged the stock as oversold with RSI near 30, and a roughly $2.05M insider sale was reported on Nov 5. Volume was elevated on the Nov 4 sell-off (2.2M shares) and has eased to about 1.3M shares, with a small rebound from the Nov 5-6 lows. The fundamentals and analyst support are strong, but the price action has not yet reflected the earnings beat.
News behind the analysis
- Corcept Therapeutics Reports Third Quarter 2026 Financial ResultsQ3 2026 revenue was $340.5M, up 64% year over year, with net income of $126.8M and diluted EPS of $1.01. The company reiterated its 2026 revenue guidance of $1.1B-$1.2B.
- Corcept Therapeutics Affirms FY2026 Sales Guidance of $1.100B-$1.200B vs $1.146B EstCorcept kept its full-year 2026 sales guidance of $1.100B-$1.200B, against a consensus estimate of $1.146B.
- Corcept Therapeutics Q3 EPS $1.01 Beats $0.81 Estimate, Sales $340.472M Beat $336.370M EstimateThird-quarter EPS of $1.01 beat the $0.81 estimate, and sales of $340.472M beat the $336.370M estimate.
- Corcept Therapeutics Q3 2026 Earnings Call TranscriptTranscript of the company's Q3 2026 earnings call, held after the third-quarter results on Nov 3.
- Corcept Therapeutics Incorporated 12-Month Price Target Raised to $142.6The average 12-month price target rose to $142.6, about 74% above the Nov 3 close, according to analysts.
- Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $173Piper Sandler reiterated its Overweight rating and raised its price target to $173.
- Top 3 Health Care Stocks You'll Regret Missing In Q4Benzinga lists Corcept as one of three healthcare stocks that appear oversold, with RSI near or below 30.
- Corcept Therapeutics Insider Sold Shares Worth $2,046,351An SEC filing shows an insider sold Corcept shares worth about $2.05M.
About Corcept Therapeutics Inc.
Corcept Therapeutics is a Redwood City, California drugmaker that develops medicines that block the effects of the stress hormone cortisol, for hormone (endocrine), cancer, metabolic and brain disorders. What sets it apart is this single focus on cortisol: it has long sold Korlym for Cushing's syndrome, and in March 2026 the FDA approved its second drug, Lifyorli (relacorilant), for platinum-resistant ovarian cancer.
How it makes money
Almost all of its revenue comes from selling its drugs. In Q3 2026 total revenue was about $340 million. Roughly 73% (about $249 million) came from Korlym and its authorized generic for Cushing's syndrome, and roughly 27% (about $91 million) came from Lifyorli, its newly launched ovarian cancer drug. The company's own 2026 revenue forecast is about $1.1–1.2 billion.
What usually moves CORT
- How fast Lifyorli sales grow in ovarian cancer
- FDA decision on relacorilant for Cushing's syndrome (decision date December 17, 2026)
- Wider screening for excess cortisol in patients with type 2 diabetes
- Competition from generics against Korlym
- Clinical trial results and revenue forecast updates